Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shapiro

Showing results (1201-1210 of 1,392) with videos related to

Pageof 140
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Blood Advances|November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor developmentB M Reipert, B Gangadharan, C J Hofbauer, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
JACC. Heart Failure|May 16, 2024
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure: A Multicohort AnalysisAmbarish Pandey, Kershaw V Patel, Matthew W Segar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2005
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonistsAnil Vasudevan, Andrew J Souers, Jennifer C Freeman, et al.
Nature Medicine|September 30, 1999
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failureS Heymans, A Luttun, D Nuyens, et al.
The Journal of Urology|August 5, 2025
Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete MetastasectomyAli Ghasemzadeh, E Jason Abel, Jose A Karam, et al.
Urology|December 13, 2025
Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ TransplantationParth V Shah, Edwin Jason Abel, Joshua D Mezrich, et al.
Pageof 140

Showing results (1201-1210 of 1,392) with videos related to

Sort By:
Pageof 140
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2016
Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal CancerGeoffrey Liu, Dongsheng Tu, Marcia Lewis, et al.
Blood Advances|November 24, 2020
The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor developmentB M Reipert, B Gangadharan, C J Hofbauer, et al.
Blood|November 24, 2011
Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patientsAmy D Shapiro, Margaret V Ragni, Leonard A Valentino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2013
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 TrialLillian L Siu, Jeremy D Shapiro, Derek J Jonker, et al.
JACC. Heart Failure|May 16, 2024
Association of High-Density Lipoprotein Parameters and Risk of Heart Failure: A Multicohort AnalysisAmbarish Pandey, Kershaw V Patel, Matthew W Segar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 2005
Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonistsAnil Vasudevan, Andrew J Souers, Jennifer C Freeman, et al.
Nature Medicine|September 30, 1999
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failureS Heymans, A Luttun, D Nuyens, et al.
The Journal of Urology|August 5, 2025
Risk Factors for First-Year Recurrence in Patients With Synchronous Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy and Complete MetastasectomyAli Ghasemzadeh, E Jason Abel, Jose A Karam, et al.
Urology|December 13, 2025
Outcomes of Patients With Localized Renal Cell Carcinoma on Immunosuppression Following Solid Organ TransplantationParth V Shah, Edwin Jason Abel, Joshua D Mezrich, et al.
Pageof 140